- Home
- CAN vs NKTX Comparison
CAN vs NKTX Comparison
Compare CAN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- NKTX
- Stock Information
- Founded
- CAN 2013
- NKTX 2015
- Country
- CAN Singapore
- NKTX United States
- Employees
- CAN N/A
- NKTX N/A
- Industry
- CAN Semiconductors
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- NKTX Health Care
- Exchange
- CAN Nasdaq
- NKTX Nasdaq
- Market Cap
- CAN 384.3M
- NKTX 123.5M
- IPO Year
- CAN 2019
- NKTX 2020
- Fundamental
- Price
- CAN $0.59
- NKTX $1.67
- Analyst Decision
- CAN Strong Buy
- NKTX Strong Buy
- Analyst Count
- CAN 6
- NKTX 6
- Target Price
- CAN $2.67
- NKTX $14.40
- AVG Volume (30 Days)
- CAN 30.3M
- NKTX 505.0K
- Earning Date
- CAN 08-14-2025
- NKTX 08-12-2025
- Dividend Yield
- CAN N/A
- NKTX N/A
- EPS Growth
- CAN N/A
- NKTX N/A
- EPS
- CAN N/A
- NKTX N/A
- Revenue
- CAN $317,009,000.00
- NKTX N/A
- Revenue This Year
- CAN $160.28
- NKTX N/A
- Revenue Next Year
- CAN $35.68
- NKTX N/A
- P/E Ratio
- CAN N/A
- NKTX N/A
- Revenue Growth
- CAN 65.68
- NKTX N/A
- 52 Week Low
- CAN $0.53
- NKTX $1.31
- 52 Week High
- CAN $3.27
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- CAN 40.92
- NKTX 39.70
- Support Level
- CAN $0.57
- NKTX $1.70
- Resistance Level
- CAN $0.72
- NKTX $1.84
- Average True Range (ATR)
- CAN 0.05
- NKTX 0.09
- MACD
- CAN -0.00
- NKTX -0.02
- Stochastic Oscillator
- CAN 7.70
- NKTX 2.38
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.